|
|
|
|
In this cohort of patients with MS who had disease refractive to multiple therapeutics before starting natalizumab treatment, magnetic resonance imaging and clinical disease activity returned, often aggressively, following discontinuation of natalizumab therapy. These findings suggest we should consider strategies to minimalize the risk of immune reconstitution inflammatory syndrome after natalizumab discontinuation. |
|